Abstract
Abstract Actovegin® (or Solcoseryl) is a deproteinized hemoderivative of calf’s blood, which contains more than 200 bioactive constituents. Screening and identification of biologically active molecule(s) is challenging due to the complexity of many constituents that may influence various cellular biochemical pathways and are found naturally in the body. Actovegin® comes in different forms including cream, gel, ointment, tablets, and injectable solution. Currently, according to section M2, Chemical and Physical Manipulation of the World Anti-Doping Code, intravenous injections of Actovegin® exceeding 100 ml is prohibited and further serial injections must be at least 12 hours apart. Although the performance-enhancing effects of Actovegin® are still anecdotal, the use of this drug has undoubtedly been widespread in sports for more than two decades. Existing findings provide promising results regarding the effect of Actovegin® in treating muscle injuries at the injected site. Further research exploring other forms of Actovegin ® (tablets, gel, cream) is encouraged to better understand the potential benefits of Actovegin® in applied sports settings.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Experimental and Applied Biomedical Research (EABR)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
